Download PDF
psychoneuro 2005; 31(9): 422-425
DOI: 10.1055/s-2005-919169
Schwerpunkt

© Georg Thieme Verlag Stuttgart · New York

Medikamentös induzierte Psychosen

Drug-induced psychosisChristian Prüter1
  • 1Krankenhaus Maria Hilf, Fachkrankenhaus für Psychiatrie und Psychotherapie, Gangelt
Further Information

Publication History

Publication Date:
06 October 2005 (online)

   Permissions and Reprints

Zusammenfassung

Es gibt eine Vielzahl von Medikamenten, die unerwünschte psychische Arzneimittelwirkungen (UAW) auslösen können. Diese Medikamente werden häufig in anderen Fachdisziplinen als der Psychiatrie eingesetzt und verordnet. Viele Medikamente können das zentrale Nervensystem beeinflussen und auch psychotische Zustandsbilder verursachen. Häufig werden solche UAWs übersehen, nicht als Medikamenteneffekt identifiziert oder fälschlicherweise als Ausdruck einer eigenständigen psychischen Störung missinterpretiert. Der folgende Artikel gibt eine Übersicht über die wichtigsten Medikamentengruppen, die eine psychotische Symptomatik induzieren können, und Hinweise zur Therapie.

Summary

The number of drugs that can induce psychiatric symptoms as side-effect is large. These drugs are often prescribed and in therapeutic use in other medical disciplines. Many of these drugs have side effects on the central nervous system and can induce psychotic symptoms. Frequently, these side effects are not diagnosed, not identified as drug side-effects or misdiagnosed as psychiatric disorders. The following article presents an overview of the important drugs that can induce psychosis and of the therapy of these psychotic syndromes.

Key words

delirium - drug induced - psychosis

Literatur

  • 1 Andrejak M, Schmitt JL, Tondriaux A. Neurologic side effects of fluoroquinolones.  Therapie. 1992;  47 415-418
    PubMedGoogle Scholar
  • 2 Baile WF. Neuropsychiatric disorders in cancer patients.  Curr Opin Oncol. 1996;  8 182-187
    PubMedGoogle Scholar
  • 3 Barry JJ, Franklin K. Amiodarone-induced delirium.  Am J Psychiatry. 1999;  156 119
    PubMedGoogle Scholar
  • 4 Bikadoroff G. Mental changes associated with tocainide, a new antiarrhythmic.  Can J Psychiatry. 1987;  32 219-221
    PubMedGoogle Scholar
  • 5 Bonhoeffer K. Die Psychosen im Gefolge von akuten Infektionen, Allgemeinerkrankungen und inneren Erkrankungen. Leipzig Wien, Deuticke 1912
    Google Scholar
  • 6 Bullinger M. Psychotropic effects of non-psychotropic drugs. Adv Drug React Acute Poisoning Rev 1987: 141-167
    Google Scholar
  • 7 Bush DF, Liss CL, Morton A. An open multicentre long-term treatment evaluation of sinemet.  Neurology. 1989;  39 101-104
    PubMedGoogle Scholar
  • 8 Campbell HM, Schubert DSP. Delirium after cessation of glucocorticoid therapy.  Gen Hosp Psychiatry. 1991;  13 270-272
    PubMedGoogle Scholar
  • 9 Clarke CWF, El-Mahdi EO. Confusion and paranoia associated with oral tocianide.  Postgrad Med. 1985;  61 79-81
    PubMedGoogle Scholar
  • 10 Cummings JL. Behavioural complications of drug treatment in Parkinson's disease.  J Am Geriatr Soc. 1991;  39 708-716
    PubMedGoogle Scholar
  • 11 Deleu D, Schmedding E. Acute psychosis as idiosyncratic reaction to quinidine: report of two cases.  BMJ. 1987;  294 1001-1002
    PubMedGoogle Scholar
  • 12 Downham TF, Cawley RA, Salley SO. Systemic toxic reactions to procaine penicillin.  Sex Transm Dis. 1978;  5 4-9
    PubMedGoogle Scholar
  • 13 Duroziez P. De deliere et du coma digitaliques.  Gaz Hebedo Med Chir. 1874;  11 780-785
    PubMedGoogle Scholar
  • 14 Eisendrath SJ, Sweeny MA. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations.  Am J Psychiatry. 1987;  144 506-507
    PubMedGoogle Scholar
  • 15 Farrington J, Stoudemire A, Tierney J. The role of ciprofloxacin in a patient with delirium due to multiple etiologies.  Gen Hosp Psychiatry. 1995;  17 47-53
    PubMedGoogle Scholar
  • 16 Fisher BW, Flowerdew G. A simple model for predicting postoperative delirium in older patients undergoing elective orthopedic surgery.  J Amer Geriat Psychiat. 1995;  43 175-178
    PubMedGoogle Scholar
  • 17 Fischer P, Assem-Hilger E. Delir/Verwirrtheitszustand. In: Förstl H (Hrsg.) Lehrbuch der Gerontopsychiatrie und -psychotherapie. Grundlagen - Klinik - Therapie. Stuttgart New York: Georg Thieme Verlag 2003: 394-408
    Google Scholar
  • 18 Francis J, Martin D, Kapoor WN. A prospective study of delirium in hospitalized elderly.  JAMA. 1990;  263 1097-1101
    CrossrefPubMedGoogle Scholar
  • 19 Galanakis P, Bickel H, Gradinger R. Acute confusional state in the elderly following hip surgery: incidence, risk factors and complications.  J Geriat Psychiatry. 2001;  16 349-355
    CrossrefPubMedGoogle Scholar
  • 20 George J, Bleasdale S, Singleton SJ. Causes and prognosis of delirium in elderly patients admitted to a district general hospital.  Age Ageing. 1997;  26 423-427
    PubMedGoogle Scholar
  • 21 Goepfert C. Häufig unerkannt: medikamentös induzierte Psychosen.  NeuroTransmitter. 2005;  16 66-71
    PubMedGoogle Scholar
  • 22 Gray SL, Katie VL, Larson EB. Drug-induced cognition disorders in the elderly.  Drug Safety. 1999;  21 101-122
    PubMedGoogle Scholar
  • 23 Greenblatt DJ, Shader RI. Digitalis toxicity. In: Shader RI (ed.) Psychiatric complications of medical drugs. New York, Raven Press 1972: 25-47
    Google Scholar
  • 24 Hollweg M, Kapfhammer HP, Krupinski M, Möller HJ. Psychopathologische Syndrome unter Behandlung mit Gyrasehemmern.  Nervenarzt. 1997;  68 38-47
    CrossrefPubMedGoogle Scholar
  • 25 Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predicitve model and interrelationship with baseline vulnerability.  JAMA. 1996;  275 852-858
    CrossrefPubMedGoogle Scholar
  • 26 Joseph CL, Siple C, McWhorter K. Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports.  J Am Geriatr Soc. 1995;  43 47-50
    PubMedGoogle Scholar
  • 27 Johnson AG, Day RO, Seldon WA. A functional psychosis precipitated by quinidine.  Med J Aust. 1990;  153 47-49
    PubMedGoogle Scholar
  • 28 Jungst G, Mohr R. Side effects of ofloxacin in clinical trials and in postmarketing surveillance.  Drugs. 1987;  1 144-149
    PubMedGoogle Scholar
  • 29 Keller H. Comparison of adverse drug effect profile of different substances such as penecillins, teracyclines, sulfonamides and quinolones.  Infection. 1991;  19 19-24
    CrossrefPubMedGoogle Scholar
  • 30 Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy.  Cardiol Rev. 2003;  11 73-93
    PubMedGoogle Scholar
  • 31 Kurlan R, Miller C, Levy R. Long term experience with pergolide treatment of advanced parkinsonism.  Neurology. 1985;  35 738-742
    PubMedGoogle Scholar
  • 32 Lautenschlager NT, Förstl H. Organic psychosis: insight into the biology of psychosis.  Curr Psych Rev. 2001;  3 319-325
    PubMedGoogle Scholar
  • 33 Levkoff S, Cleary P, Liptzin B. Epidemiology of delirium: an overbiew of research issues and findings.  International Psychogeriatrics. 1991;  3 149-167
    CrossrefPubMedGoogle Scholar
  • 34 Lieberman AN, Goldstein M, Gopinathan G. Further studies with pergolide in Parkinsons disease.  Neurology. 1982;  32 1182-1184
    PubMedGoogle Scholar
  • 35 Lieberman AN, Goldstein M, Gopinathan G. D-1 and D-2 agonists in Parkinsons disease.  Can J Neurol Sci. 1987;  14 466-473
    PubMedGoogle Scholar
  • 36 Lupien S, Lecours AR, Lussier I. Basal cortisol levels and cognitive decline in human aging.  J Neurosci. 1994;  14 2893-2903
    PubMedGoogle Scholar
  • 37 Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer.  J Affect Disord. 1998;  50 245-251
    CrossrefPubMedGoogle Scholar
  • 38 Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly.  Drugs & Aging. 1999;  15 15-28
    PubMedGoogle Scholar
  • 39 Morrison RL, Katz IR. Drug related cognitive impairment: current progress and recurrent problems.  Annu Rev Gerontol Geriatr. 1989;  9 232-279
    PubMedGoogle Scholar
  • 40 Mueller TH, Beeber AR. Delirium from valproic acid with lamotrigine.  Am J Psychiatry. 2004;  161 1128-1129
    PubMedGoogle Scholar
  • 41 Mula M, Trimble MR, Lhatoo SD, Sander JWAS. Topiramate and psychiatric adverse events in patients with epilepsy.  Epilepsia. 2003;  44 659-663
    CrossrefPubMedGoogle Scholar
  • 42 Mulhall JP, Bergmann LS. Cirpofloxacin-induced acute psychosis.  Urology. 1995;  46 102-103
    CrossrefPubMedGoogle Scholar
  • 43 Nicholls PJN. Neurotoxicity of penicillin.  J Antimikrob Chemother. 1980;  6 161-165
    PubMedGoogle Scholar
  • 44 O'Keeffe ST, Devlin JG. Delirium and the dexamethasone suppression test in the elderly.  Neuropsychobiology. 1994;  30 153-156
    PubMedGoogle Scholar
  • 45 O'Keeffe ST, Lavan SN. The clinical significance of delirium subtypes.  Age Ageing. 1999;  28 115-119
    CrossrefPubMedGoogle Scholar
  • 46 Patten SB, Love EJ. Neuropsychiatric adverse reactions: passive reports to Health and Welfare Canada's Adverse Drug Reaction Database (1965 - present).  Int J Psychiatry Med. 1994;  24 45-62
    PubMedGoogle Scholar
  • 47 Patten SB, Neutel I. Corticosteroid-induced adverse psychiatric effects.  Drug Safety. 2000;  22 111-122
    CrossrefPubMedGoogle Scholar
  • 48 Perantie DC, Brown ES. Corticosteroids, Immune Suppression, and Psychosis.  Current Psychiatric Reports. 2002;  4 171-176
    PubMedGoogle Scholar
  • 49 Rice H, Haltzman S, Tucek C. Mania associated with procainamid.  Am J Psychiatry. 1988;  145 129-130
    PubMedGoogle Scholar
  • 50 Sarvay SM, Marke J, Steinberg MD. „Doom anxiety” and delirium in lidocaine toxicity.  Am J Psychiatry. 1987;  144 159-163
    PubMedGoogle Scholar
  • 51 Schaefer M, Engelbrecht MA, Gut O, Fiebich BI, Bauer J, Schmidt F, Grunze H, Lieb K. Interferon alpha (IFN a) and psychiatric syndromes. A review.  Prog Neur Psychopharm Biol Psychiatry. 2002;  26 731-746
    CrossrefPubMedGoogle Scholar
  • 52 Schah PM, Mulert R. Safety profile of quinolones.  Eur Urol. 1990;  17 46-51
    PubMedGoogle Scholar
  • 53 Schliamser SE, Cars O, Norrby SR. Neurotoxicity of beta-lactam antibiotics: predisposing factors and pathogenesis.  J Antimicrob Chemother. 1991;  27 405-425
    CrossrefPubMedGoogle Scholar
  • 54 Sirois F. Steroid psychosis: a review.  Gen Hosp Psychiatry. 2003;  25 27-33
    CrossrefPubMedGoogle Scholar
  • 55 Slaker RA, Danielson B. Neurotoxicity associated with ceftazidirne therapy in geriatric patients with renal dysfunction.  Pharmacotherapy. 1991;  4 351-352
    PubMedGoogle Scholar
  • 56 Smith DB. Cognitive effects of antiepileptic drugs. In: Smith D, Treiman D, Trimble MR (eds) Neurobehavioral problems in epilepsy. New York: Raven Press 1991: 197-212
    Google Scholar
  • 57 Smith H, Janz TG, Erker M. Digoxin toxicity presenting as altered mental status in a patient with severe chronic obstructive lung disease.  Heart Lung. 1992;  21 78-80
    PubMedGoogle Scholar
  • 58 Smith HL. Cerebral manifestations of digitalis intoxication.  Mayo Clin Proc. 1938;  13 574-575
    PubMedGoogle Scholar
  • 59 Snavely SR, Hodges GR. The neurotoxicity of antibacterial agents.  Ann Intern Med. 1984;  101 92-104
    CrossrefPubMedGoogle Scholar
  • 60 Sternbach H, State R. Antibiotics: neuropsychiatric effects and psychotropic interactions.  Harv Rev Psychiatry. 1997;  5 214-226
    PubMedGoogle Scholar
  • 61 Stoudemire A, Anfinson T, Edward J. Corticosteroid-induced delirium, and dependency.  Gen Hosp Psychiatry. 1996;  18 196-202
    PubMedGoogle Scholar
  • 62 Tack KJ, Smith JA. The safety profile of ofloxacin.  Am J Med. 1989;  87 78S-81S
    PubMedGoogle Scholar
  • 63 The Medical Letter I. Drugs that cause psychiatric symptoms. Med Lett Drugs Ther 35: 65-70
    Google Scholar
  • 64 Thomas RJ, Reagan DR. Association of a Tourette-like syndrome with ofloxazin.  Ann Pharmacother. 1996;  30 138-141
    PubMedGoogle Scholar
  • 65 Trohman RG, Castellanos D, Castellanos A. Amiodarone-induced delirium.  Ann Intern Med. 1988;  108 68-69
    PubMedGoogle Scholar
  • 66 Tuxen MK, Hansen SW. Neurotoxicity secondary to antineoplastic drugs.  Cancer Treat Rev. 1994;  20 191-214
    CrossrefPubMedGoogle Scholar
  • 67 Weinrich S, Sarna L. Delirium in the older person with cancer.  Cancer. 1994;  74 2079-2091
    PubMedGoogle Scholar
  • 68 Young BK, Camicioli R, Ganzini L. Neuropsychiatric adverse effects of antiparkinsonian drugs: characteristics, evaluation and treatment.  Drugs Aging. 1997;  10 367-383
    CrossrefPubMedGoogle Scholar

Korrespondenzadresse:

Dr. med. Christian Prüter

Gangelter Einrichtungen, Krankenhaus Maria Hilf

Fachkrankenhaus für Psychiatrie und Psychotherapie

Bruchstraße 6

52538 Gangelt

Email: chprueter@yahoo.de